Ollin Biosciences raised $330M led by TCGX and ARCH. Blackstone, CPP, and T. Rowe Price joined the oversubscribed round, signaling strong crossover demand for late-stage biotech.
Ollin Biosciences raised $330 million in an oversubscribed Series B round, the Austin-based company announced July 1. TCGX and ARCH Venture Partners co-led the financing. The syndicate included Blackstone Multi-Asset Investing, CPP Investments, and a16z Bio+Health. RA Capital Management and accounts advised by T. Rowe Price Investment Management also participated, alongside Commodore Capital, Mubadala Capital, Monograph Capital, and a sovereign wealth fund.
The round's size and roster provide a snapshot of where crossover capital is flowing in biotech. Ollin focuses on vision-threatening diseases, an area that has drawn increasing attention from large institutional investors. The company's pipeline includes therapies for retinal conditions, though specific candidates were not detailed in the release.
The oversubscribed nature of the round suggests supply of late-stage private deals trails demand. That dynamic can support valuations for public ophthalmology biotechs, though direct readthroughs from private rounds to public multiples are rarely mechanical. Each company's clinical data, trial design, and path to market differ.
Crossover investors like Blackstone and CPP Investments bring long-duration capital, often willing to hold through multiple clinical milestones. T. Rowe Price's involvement via advised accounts adds a public-market lens, frequently a precursor to IPO interest. The presence of a sovereign wealth fund underscores the global hunt for innovative therapeutics.
Ollin is clinical-stage, so the $330 million will fund ongoing and new trials. No timeline for an IPO was provided. The company said it expects to begin Phase 3 studies in the fourth quarter.
The round is among the larger private biotech financings in 2026, reflecting a recovery in crossover appetite after a 2023-2024 pullback. For the broader sector, it signals that capital remains accessible for companies with clear therapeutic focus and strong backers.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.